- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Study Finds Genetic Markers Linked to Beginning Phase of Parkinson
Researchers have identified a group of genetic variants related to the starting point of Parkinson disease.
Researchers have identified a group of genetic variants related to the starting point of Parkinson disease, possibly enabling research for new therapeutic targets, according to a recent study published by Movement Disorders.
The researchers evaluated genetic markers—DNA segments with chromosome-identifiable locations—that adjust the starting age of the disease. The study collected blood samples from more than 900 patients of a hospital clinic to evaluate these genetic markers.
“Single nucleotide polymorphisms (SNPs) in the α‐synuclein (SNCA) gene are associated with differential risk and age at onset (AAO) of both idiopathic and Leucine‐rich repeat kinase 2 (LRRK2)‐associated Parkinson's disease (PD),” the study explained. “Yet potential combinatory or synergistic effects among several modulatory SNPs for PD risk or AAO remain largely underexplored.”
The blood sample results demonstrated that a group of genetic markers of the mTOR metabolic pathway, combined, contribute to adjust the starting age of Parkinson disease, the authors explained.
"There are known genetic markers, such as the genetic markers of the synuclein gene, which are associated with an earlier start of the symptoms, but in this study we focused on the influence of the association of other markers which were not known yet," Cristina Malagelada, UBNeuro researcher, said in a statement.
Additionally, identifying this group of markers, which links the neuronal survival, synaptic plasticity, and protein synthesis, an independent second population of affected patients of 4000 patients can be confirmed.
“Identifying this group of markers that influence each other and which condition the starting point of the disease allow delimiting the research of new therapeutic targets in these candidate genes,” noted Malagelada.
Reference
Fernández‐Santiago R, Martín‐Flores N, Antonelli F, et al. SNCA and mTOR pathway single nucleotide polymorphisms interact to modulate the age at onset of Parkinson's disease. Movement Disorders, 2019;34(9):1333. doi:10.1002/mds.27770.
Major Study Expands in Hopes to Cure Parkinson Disease
April 19th 2022April is Parkinson’s Disease Awareness month, and on this episode of Managed Care Cast, we take a look at the Parkinson's Progression Markers Initiative (PPMI), a study from the Michael J. Fox Foundation for Parkinson's Research (MJFF). The multicenter, international study aims to end Parkinson disease, which is expected to double worldwide by 2040, to more than 14 million people.
Listen
PD Worsens QOL, Increases Depression in Men More Than Women in the Southeast
February 17th 2023The southeastern areas of the country have worse health outcomes and health-related quality of life (HRQOL) compared with other parts of the United States, with high rates of diabetes, obesity, cancer, and cardiovascular disease.
Read More
An Inside Look at Innovations by MJFF to Assist the Parkinson Community Amid the COVID-19 Pandemic
May 26th 2020On this episode of Managed Care Cast, we speak with Rachel Dolhun, MD, vice president of Medical Communications at The Michael J. Fox Foundation for Parkinson Research, about recent innovations by The Michael J. Fox Foundation to assist patients and families of patients with Parkinson disease in adjusting to this new normal.
Listen
